SLGL (sol-gel.com) יחס שווי שוק לשווי בספרים

Sol-Gel Technologies (SLGL) focuses on innovative delivery methods for dermatological agents, benefiting from royalty payments for Epsolay and Twyneo, with the indicator standing at 4.72. Market dynamics for the securities reflect the asset's current quotes. The business relies on silica microencapsulation and patent protection, while stable revenue from topical agents offsets the impact of external economic shocks due to the specifics of clinical cycles.

This ratio compares the market value of shares with net assets to determine the degree of business overvaluation. The value is sensitive to balance sheet revaluations in operating reports. By analyzing the current ratio of the company's value to its book capitalization, an investor separates market noise from fundamental value. For Sol-Gel Technologies (SLGL), this indicator reflects the capitalization of intellectual potential in the field of microencapsulation. An increase in this metric confirms the market's bet on the success of its proprietary dermatological products.